Gujarat Kidney & Super Speciality Ltd
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]
- Market Cap ₹ 1,228 Cr.
- Current Price ₹ 156
- High / Low ₹ 210 / 98.2
- Stock P/E 64.6
- Book Value ₹ 33.4
- Dividend Yield 0.00 %
- ROCE 14.5 %
- ROE 11.1 %
- Face Value ₹ 2.00
Pros
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 172 days.
- Working capital days have increased from 55.7 days to 91.1 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of Nifty IPO BSE IPO BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| 0 | 5 | 40 | 82 | 126 | |
| Sales growth | +744% | +104% | +154% | ||
| 0 | 3 | 24 | 55 | 94 | |
| Operating Profit | -0 | 2 | 17 | 27 | 32 |
| OPM % | 41% | 41% | 33% | 25% | |
| 0 | 1 | 0 | 1 | 2 | |
| Interest | 0 | 0 | 1 | 2 | 3 |
| Depreciation | 0 | 0 | 3 | 5 | 6 |
| Profit before tax | -0 | 2 | 13 | 21 | 25 |
| Tax % | 0% | 25% | 26% | 21% | |
| -0 | 2 | 10 | 17 | 20 | |
| EPS in Rs | -0.00 | 0.49 | 1.66 | 1.97 | 2.41 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 154% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1058% |
| TTM: | 68% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 16% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.20 | 0.20 | 11 | 16 | 16 |
| Reserves | 0 | 11 | 15 | 237 | 248 |
| 0 | 6 | 8 | 29 | 30 | |
| 4 | 4 | 21 | 16 | 33 | |
| Total Liabilities | 4 | 21 | 55 | 298 | 327 |
| 0 | 14 | 31 | 129 | 149 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 12 | 12 |
| 4 | 7 | 24 | 157 | 165 | |
| Total Assets | 4 | 21 | 55 | 298 | 327 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 0 | 1 | 14 | -4 | |
| 0 | 0 | -18 | -214 | |
| 0 | -0 | 6 | 228 | |
| Net Cash Flow | 0 | 1 | 2 | 11 |
| Free Cash Flow | 0 | 2 | -5 | -98 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 0% | 70% | 99% | 21% |
Ratios
Consolidated / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 321 | 138 | 172 | |
| Inventory Days | ||||
| Days Payable | ||||
| Cash Conversion Cycle | 321 | 138 | 172 | |
| Working Capital Days | 100 | -24 | 91 | |
| ROCE % | 19% | 52% | 14% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Average Bed Occupancy Rate % ・Includes some standalone data |
|
|||
| Average Revenue per Occupied Bed INR ・Includes some standalone data |
||||
| Operational Beds beds ・Includes some standalone data |
||||
| IPD Volume admissions |
||||
| OPD Volume visits |
||||
| Acquired Ownership Stake - Ashwini Medical Centre % ・Standalone data |
||||
| Acquired Ownership Stake - Harmony Medicare Private Limited % ・Standalone data |
||||
| Acquired Ownership Stake - Parekhs Hospital Private Limited % ・Standalone data |
||||
| Acquired Ownership Stake - Patel Multispeciality Hospital and ICU % ・Standalone data |
||||
| Acquired Ownership Stake - Patel Pharmacy % ・Standalone data |
||||
| Acquisition Cost - Parekhs Hospital Private Limited INR ・Standalone data |
||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper publication for Unaudited Financial Statements for the Quarter ended September 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of Q2 FY27 earnings call uploaded on November 5, 2026.
- Announcement under Regulation 30 (LODR)-Investor Presentation
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor Presentation for scheduled Conference Call on November 05, 2026
Concalls
-
Nov 2026Transcript PPT REC
-
Nov 2026PPT
Business Profile[1]
Gujarat Kidney and Super Speciality Limited is a regional healthcare operator in central Gujarat, running a chain of mid-sized multi-speciality hospitals focused on secondary and tertiary care.